Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? - Wikidata - wikimedia - TriplyDB

Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?

Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?

http://www.wikidata.org/entity/Q37066925

about

HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents.Recent advances in immuno-oncology and its application to urological cancers.Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy.New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.Modeling of Interactions between Cancer Stem Cells and their Microenvironment: Predicting Clinical Response.

P2860

Q26739120-1F584831-50CD-416B-9E6D-80D525F93CEA Q37626311-FCC17AAD-3236-49DF-8B4B-665D5DBA9C35 Q38783324-A8D11837-772E-49FA-8B58-325BEE3B47DC Q38819745-19DB80FA-856C-48B2-BC16-C0716DF5EBD1 Q38962024-CEA7FB0B-E24C-4926-BCF1-8DFFA79D68B3 Q39271075-4E356258-A14F-4F56-9E31-C930FBBFEA23 Q46047154-FF184273-F265-4224-8509-72985ABE858F Q47561430-525C9CBF-237E-4454-8CE6-0031CFB86E5E

P2860

Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?

http://www.wikidata.org/entity/Q37066925

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 February 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?

@en

Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?

@nl

type

label

Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?

@en

Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?

@nl

prefLabel

Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?

@en

Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?

@nl

P1433

Q37066925-9BE6A17B-F6A7-44B1-AF54-A51A7A62B599

P1476

Q37066925-28F83B63-EADF-4D3F-99B7-3AD4F5FEF3B2

P2093

Q37066925-3B493D70-F6F3-4692-8FF5-E542064C59B7

Q37066925-B396F4BD-5FE8-4C36-8926-6878F1748435

Q37066925-CD5FB85E-0145-4F81-BB17-51371C6899ED

P2860

Q37066925-00486C93-A0E4-4AEC-B4AC-929270C2B0E8

Q37066925-05FB3948-2BD4-47B5-B572-2D9AD39E3B04

Q37066925-0AB840B8-3E07-4798-856B-1CB6CEF2A3AA

Q37066925-0B37F191-C2FC-4B18-81EB-A5409FDC0048

Q37066925-0D19DECD-F16B-449E-ABD7-D865F219D793

Q37066925-17F85A22-9A3B-4660-BB38-494493BA4BBD

Q37066925-1D5973B0-8EF4-4D7B-8022-C3D0D7A23FD4

Q37066925-1E3F0CD1-8D48-4CAF-8373-8924EC8FF3E2

Q37066925-21003CCA-5F60-4471-B519-5511F6FCE261

Q37066925-21EE4EE3-898F-4BBD-8650-D58670C930B0

P304

Q37066925-64774B70-05A2-4C1E-A964-B93494096745

P31

Q37066925-91ED3753-09D1-47F4-9D7F-CF9A8DD9821F

P356

Q37066925-35D8511F-B243-4C75-8998-079F0C2243BD

P433

Q37066925-3F71EC16-AC10-4DF6-80F4-937A2DB4CC22

P478

Q37066925-09731738-586E-48A2-BFC2-910CB01D417B

P577

Q37066925-2F1E3CD0-F96B-450A-B3DB-5E7055FAAC28

P698

Q37066925-332BE960-18EB-45C5-9ED7-80E0D373817E

P921

Q37066925-0DF685CA-415D-4EFA-8542-4FEDB2EE655B

P932

Q37066925-F12EA107-9113-4598-ADE2-FE2CD0484516

P356

J.SMIM.2016.01.001

P1433

Seminars in Immunology

P1476

Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?

@en

P2093

Antoni Ribas

http://www.w3.org/2001/XMLSchema#string

Lidia Robert

http://www.w3.org/2001/XMLSchema#string

Siwen Hu-Lieskovan

http://www.w3.org/2001/XMLSchema#string

P2860

Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Cancer regression in patients after transfer of genetically engineered lymphocytes

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

Targeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer Immunity

P304

73-80

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.SMIM.2016.01.001

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26861544

http://www.w3.org/2001/XMLSchema#string

P921

P932

4933650

http://www.w3.org/2001/XMLSchema#string